1. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine.
- Author
-
Tang T, Targan SR, Li ZS, Xu C, Byers VS, and Sandborn WJ
- Subjects
- Acanthaceae chemistry, Adolescent, Adult, Aged, China, Colitis, Ulcerative physiopathology, Dietary Supplements, Double-Blind Method, Female, Humans, Male, Middle Aged, Severity of Illness Index, Treatment Outcome, Young Adult, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Colitis, Ulcerative drug therapy, Mesalamine therapeutic use, Plant Preparations therapeutic use
- Abstract
Background: Andrographis paniculata is an herbal mixture used to treat inflammatory diseases. An extract of the herb, HMPL-004, inhibits TNF-α and IL-1β, and prevents colitis in animal models., Aim: To determine the efficacy and safety of HMPL-004 in patients with mild-to-moderate ulcerative colitis., Methods: A randomised, double-blind, multicentre, 8-week parallel group study was conducted using HMPL-004 1200 mg/day compared with 4500 mg/day of slow release mesalazine (mesalamine) granules in patients with mild-to-moderately active ulcerative colitis. Disease activity was assessed at baseline and every 2 weeks for clinical response, and at baseline and 8 weeks by colonoscopy., Results: One hundred and twenty patients at five centres in China were randomised and dosed. Clinical remission and response were seen in 21% and 76% of HMPL-004-treated patients, and 16% and 82% of mesalazine-treated patients. By colonoscopy, remission and response were seen in 28% and 74% of HMPL-004-treated patients and 24% and 71% of mesalazine-treated patients, respectively. There was no significant difference between the two treatment groups., Conclusion: HMPL-004 may be an efficacious alternative to mesalazine in ulcerative colitis., (© 2010 Blackwell Publishing Ltd.)
- Published
- 2011
- Full Text
- View/download PDF